Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Receivables - Accured (2023 - 2025)

Kura Oncology (KURA) has disclosed Receivables - Accured for 3 consecutive years, with $3.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Accured rose 15.15% to $3.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.8 million, a 15.15% increase, with the full-year FY2025 number at $3.8 million, up 15.15% from a year prior.
  • Receivables - Accured was $3.8 million for Q4 2025 at Kura Oncology, up from $3.3 million in the prior quarter.
  • In the past five years, Receivables - Accured ranged from a high of $3.9 million in Q1 2025 to a low of $900000.0 in Q1 2023.
  • A 3-year average of $2.3 million and a median of $1.9 million in 2024 define the central range for Receivables - Accured.
  • Peak YoY movement for Receivables - Accured: skyrocketed 200.0% in 2024, then rose 15.15% in 2025.
  • Kura Oncology's Receivables - Accured stood at $1.1 million in 2023, then surged by 200.0% to $3.3 million in 2024, then grew by 15.15% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Receivables - Accured are $3.8 million (Q4 2025), $3.3 million (Q3 2025), and $3.6 million (Q2 2025).